Different methods and settings for glucose monitoring for gestational diabetes during pregnancy

被引:44
|
作者
Raman, Puvaneswary [1 ]
Shepherd, Emily [2 ]
Dowswell, Therese [3 ]
Middleton, Philippa [4 ]
Crowther, Caroline A. [2 ,5 ]
机构
[1] King Edward Mem Hosp, Perth, WA, Australia
[2] Univ Adelaide, Robinson Res Inst, ARCH Australian Res Ctr Hlth Women & Babies, Discipline Obstet & Gynaecol, Adelaide, SA 5006, Australia
[3] Univ Liverpool, Dept Womens & Childrens Hlth, Cochrane Pregnancy & Childbirth Grp, Liverpool, Merseyside, England
[4] South Australian Hlth & Med Res Inst, Hlth Mothers Babies & Children, Adelaide, SA, Australia
[5] Univ Auckland, Liggins Inst, Auckland, New Zealand
来源
COCHRANE DATABASE OF SYSTEMATIC REVIEWS | 2017年 / 10期
基金
英国医学研究理事会;
关键词
RANDOMIZED CONTROLLED-TRIAL; BLOOD-GLUCOSE; GLYCEMIC CONTROL; INTERNATIONAL ASSOCIATION; TELEMEDICINE SYSTEM; TELE-MUM; MELLITUS; MANAGEMENT; WOMEN; OUTCOMES;
D O I
10.1002/14651858.CD011069.pub2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Incidence of gestational diabetes mellitus (GDM) is increasing worldwide. Blood glucose monitoring plays a crucial part in maintaining glycaemic control in women with GDM and is generally recommended by healthcare professionals. There are several different methods for monitoring blood glucose which can be carried out in different settings (e.g. at home versus in hospital). Objectives The objective of this review is to compare the effects of different methods and settings for glucose monitoring for women with GDM on maternal and fetal, neonatal, child and adult outcomes, and use and costs of health care. Search methods We searched the Cochrane Pregnancy and Childbirth Group Trials Register (30 September 2016) and reference lists of retrieved studies. Selection criteria Randomised controlled trials (RCTs) or quasi-randomised controlled trials (qRCTs) comparing different methods (such as timings and frequencies) or settings, or both, for blood glucose monitoring for women with GDM. Data collection and analysis Two authors independently assessed study eligibility, risk of bias, and extracted data. Data were checked for accuracy. We assessed the quality of the evidence for the main comparisons using GRADE, for: -primary outcomes for mothers: that is, hypertensive disorders of pregnancy; caesarean section; type 2 diabetes; and -primary outcomes for children: that is, large-for-gestational age; perinatal mortality; death or serious morbidity composite; childhood/adulthood neurosensory disability; -secondary outcomes for mothers: that is, induction of labour; perineal trauma; postnatal depression; postnatal weight retention or return to pre-pregnancy weight; and -secondary outcomes for children: that is, neonatal hypoglycaemia; childhood/adulthood adiposity; childhood/adulthood type 2 diabetes. Main results We included 11 RCTs (10 RCTs; one qRCT) that randomised 1272 women with GDM in upper-middle or high-income countries; we considered these to be at a moderate to high risk of bias. We assessed the RCTs under five comparisons. For outcomes assessed using GRADE, we downgraded for study design limitations, imprecision and inconsistency. Three trials received some support from commercial partners who provided glucose meters or financial support, or both. Main comparisons Telemedicine versus standard care for glucose monitoring (five RCTs): we observed no clear differences between the telemedicine and standard care groups for the mother, for: -pre-eclampsia or pregnancy-induced hypertension (risk ratio (RR) 1.49, 95% confidence interval (CI) 0.69 to 3.20; 275 participants; four RCTs; very low quality evidence); -caesarean section (average RR 1.05, 95% CI 0.72 to 1.53; 478 participants; 5 RCTs; very low quality evidence); and -induction of labour (RR 1.06, 95% CI 0.63 to 1.77; 47 participants; 1 RCT; very low quality evidence); or for the child, for: -large-for-gestational age (RR 1.41, 95% CI 0.76 to 2.64; 228 participants; 3 RCTs; very low quality evidence); -death or serious morbidity composite (RR 1.06, 95% CI 0.68 to 1.66; 57 participants; 1 RCT; very low quality evidence); and -neonatal hypoglycaemia (RR 1.14, 95% CI 0.48 to 2.72; 198 participants; 3 RCTs; very low quality evidence). There were no perinatal deaths in two RCTs (131 participants; very low quality evidence). Self-monitoring versus periodic glucose monitoring (two RCTs): we observed no clear differences between the self-monitoring and periodic glucose monitoring groups for the mother, for: -pre-eclampsia (RR 0.17, 95% CI 0.01 to 3.49; 58 participants; 1 RCT; very low quality evidence); and -caesarean section (average RR 1.18, 95% CI 0.61 to 2.27; 400 participants; 2 RCTs; low quality evidence); or for the child, for: -perinatal mortality (RR 1.54, 95% CI 0.21 to 11.24; 400 participants; 2 RCTs; very low quality evidence); -large-for-gestational age (RR 0.82, 95% CI 0.50 to 1.37; 400 participants; 2 RCTs; low quality evidence); and -neonatal hypoglycaemia (RR 0.64, 95% CI 0.39 to 1.06; 391 participants; 2 RCTs; low quality evidence). Continuous glucose monitoring system (CGMS) versus self-monitoring of glucose (two RCTs): we observed no clear differences between the CGMS and self-monitoring groups for the mother, for: -caesarean section (RR 0.91, 95% CI 0.68 to 1.20; 179 participants; 2 RCTs; very low quality evidence); or for the child, for: -large-for-gestational age (RR 0.67, 95% CI 0.43 to 1.05; 106 participants; 1 RCT; very low quality evidence) and -neonatal hypoglycaemia (RR 0.79, 95% CI 0.35 to 1.78; 179 participants; 2 RCTs; very low quality evidence. There were no perinatal deaths in the two RCTs (179 participants; very low quality evidence). Other comparisons Modem versus telephone transmission for glucose monitoring (one RCT): none of the review's primary outcomes were reported in this trial Postprandial versus preprandial glucose monitoring (one RCT): we observed no clear differences between the postprandial and preprandial glucose monitoring groups for the mother, for: -pre-eclampsia (RR 1.00, 95% CI 0.15 to 6.68; 66 participants; 1 RCT); -caesarean section (RR 0.62, 95% CI 0.29 to 1.29; 66 participants; 1 RCT); and -perineal trauma (RR 0.38, 95% CI 0.11 to 1.29; 66 participants; 1 RCT); or for the child, for: -neonatal hypoglycaemia (RR 0.14, 95% CI 0.02 to 1.10; 66 participants; 1 RCT). Therewere fewer large-for-gestational-age infants born tomothers in the postprandial comparedwith the preprandial glucosemonitoring group (RR 0.29, 95% CI 0.11 to 0.78; 66 participants; 1 RCT). Authors' conclusions Evidence from 11 RCTs assessing different methods or settings for glucose monitoring for GDM suggests no clear differences for the primary outcomes or other secondary outcomes assessed in this review. However, current evidence is limited by the small number of RCTs for the comparisons assessed, small sample sizes, and the variable methodological quality of the RCTs. More evidence is needed to assess the effects of different methods and settings for glucose monitoring for GDM on outcomes for mothers and their children, including use and costs of health care. Future RCTs may consider collecting and reporting on the standard outcomes suggested in this review.
引用
收藏
页数:158
相关论文
共 50 条
  • [41] Risk of Subsequent Hypertension and Diabetes in Women With Hypertension During Pregnancy and Gestational Diabetes
    Hwu, Lien-Jen
    Sung, Fung-Chang
    Mou, Chih-Hsin
    Wang, I-Kuan
    Shih, Hsin-Hsin
    Chang, Yin-Yi
    Tzeng, Ya-Ling
    MAYO CLINIC PROCEEDINGS, 2016, 91 (09) : 1158 - 1165
  • [42] Gestational Diabetes and Maternal Weight Management During and After Pregnancy
    Chakkalakal, Rosette J.
    Hackstadt, Amber J.
    Trochez, Ricardo
    Gregory, Rebecca
    Elasy, Tom A.
    JOURNAL OF WOMENS HEALTH, 2019, 28 (05) : 646 - 653
  • [43] Free Thyroxine During Early Pregnancy and Risk for Gestational Diabetes
    Haddow, James E.
    Craig, Wendy Y.
    Neveux, Louis M.
    Palomaki, Glenn E.
    Lambert-Messerlian, Geralyn
    Malone, Fergal D.
    D'Alton, Mary E.
    PLOS ONE, 2016, 11 (02):
  • [44] Pre-Gestational Diabetes and Pregnancy Outcomes
    Ali, Dalal S.
    Davern, Recie
    Rutter, Eimear
    Coveney, Ciara
    Devine, Hilary
    Walsh, Jennifer M.
    Higgins, Mary
    Hatunic, Mensud
    DIABETES THERAPY, 2020, 11 (12) : 2873 - 2885
  • [45] Effects of different dietary patterns during pregnancy on birth outcomes and glucose parameters in women with gestational diabetes mellitus: A systematic review and meta-analysis
    Lin, Qiulin
    Zhang, Zhiqiang
    Meng, Qingchong
    Xie, Yali
    Liu, Zhengxiang
    Hu, Chunqiu
    Wang, Guoxiu
    Qin, Panzhu
    Bo, Qingli
    PRIMARY CARE DIABETES, 2023, 17 (04) : 287 - 308
  • [46] Mean Glucose and Gestational Weight Gain as Predictors of Large-for-Gestational-Age Infants in Pregnant Women with Type 1 Diabetes Using Continuous Glucose Monitoring
    Soholm, Julie Carstens
    Norgaard, Sidse K.
    Norgaard, Kirsten
    Clausen, Tine D.
    Damm, Peter
    Mathiesen, Elisabeth R.
    Ringholm, Lene
    DIABETES TECHNOLOGY & THERAPEUTICS, 2024, 26 (08) : 536 - 546
  • [47] Gestational Diabetes, Obesity, and Metabolic Syndrome Diagnosed During Pregnancy
    Baliutaviciene, Dalia
    Buinauskiene, Jurate B.
    Petrenko, Vladimiras
    Danyte, Evalda
    Zalinkevicius, Rimantas
    METABOLIC SYNDROME AND RELATED DISORDERS, 2012, 10 (03) : 214 - 217
  • [48] Self-monitoring of blood glucose levels among pregnant individuals with gestational diabetes: a systematic review and meta-analysis
    Yeh, Ping Teresa
    Kennedy, Caitlin Elizabeth
    Rhee, Dong Keun
    Zera, Chloe
    Tuncalp, Ozge
    Lucido, Briana
    de Leon, Rodolfo Gomez Ponce
    Narasimhan, Manjulaa
    FRONTIERS IN GLOBAL WOMENS HEALTH, 2023, 4
  • [49] Screening for gestational diabetes in pregnancy in Northwestern Ontario
    Poirier, Jenna
    Kattini, Ribal
    Kelly, Len
    Madden, Sharen
    Voth, Brenda
    Dooley, Joe
    Marazan, Brent
    Hummelen, Ruben
    CANADIAN JOURNAL OF RURAL MEDICINE, 2020, 25 (02) : 61 - 66
  • [50] Clinical Effectiveness of Continuous Glucose Monitoring in Pregnancies Affected by Type 1 Diabetes
    Gao, Valerie
    Snell-Bergeon, Janet K.
    Malecha, Emily
    Johnson, Carly A.
    Polsky, Sarit
    DIABETES TECHNOLOGY & THERAPEUTICS, 2024, 26 (08) : 526 - 535